

**Axumin™ (fluciclovine F 18) Injection**

**Clinical Bibliography**

Bach-Gansmo T, Nanni C, Nieh PT, et al. Multi-site experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) PET/CT imaging in the staging of biochemically recurrent prostate cancer. *J Urol* 2016;doi:10.1016/j.juro.2016.09.117.

Jani, AB, Schreibmann E, Rossi, PJ, et al. Impact of fluciclovine (18F) positron emission tomography on target volume definition for post-prostatectomy salvage radiotherapy: initial findings from a randomized trial. *J Nuc Med* 2016;doi:10.2967/jnumed.116.176057

Kairemo K, Rasuloova N, Partanen K, Joensuu T. Preliminary clinical experience of trans-1-amino-3-(18F)-fluorocyclobutanecarboxylic Acid (anti-(18F)-FACBC) PET/CT imaging in prostate cancer patients. *Biomed Res Int.* 2014;305182.doi:10.1155/2014/305182.bio

McParland BJ, Wall A, Johansson J, et al. The clinical safety, biodistribution and internal radiation dosimetry of [18F] fluciclovine in healthy adult volunteers. *Eur J Nucl Med Mol Imaging* 2013;40:1256–64

Nanni C, Zanoni L, Pultrone C, et al. 18F-FACBC (anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial. *Eur J Nucl Med* 2016;43:1601-10

Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. *J Nucl Med* 2007;48:1017-20

Odevole OA, Oyenuga OA, Tade F, et al. Reproducibility and reliability of anti-3-[18F]FACBC uptake measurements in background structures and malignant lesions on follow-up PET-CT in prostate carcinoma: an exploratory analysis. *Mol Imaging Biol* 2015;17:277-83

Odevole OA, Tade FI, Nieh PT, et al. Recurrent prostate cancer detection with anti-3-[(18F)F]FACBC PET/CT: comparison with CT. *Eur J Nucl Med Mol Imaging* 2016;43:1773-83

Oka S, Hattori R, Kurosaki F, et al. A preliminary study of anti-1-amino-3-18f-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. *J Nucl Med* 2007;48:46-55

Oka S, Okudaira H, Yoshida Y, Schuster DM, et al. Transport mechanisms of trans-1-amino-3-fluoro[1-14C]cyclobutanecarboxylic acid in prostate cancer cells. *Nucl Med Biol* 2012;39:109-19

Okudaira H, Shikano N, Nishii R, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18 F-fluorocyclobutanecarboxylic acid in human prostate cancer. *J Nucl Med* 2011;52:822-9

Okudaira H, Nakanishi T, Oka S, et al. Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in *Xenopus laevis* oocytes expressing human ASCT2 and SNAT2. *Nuc Med & Biol* 2013;40:670-5

Ren J, Yuan L, Wen G, Yang J. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis. *Acta Radiol* 2015;doi:10.1177/0284185115581541

# AXUMIN™

## Fluciclovine F 18 Injection

Schuster DM, Votaw, JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48:11a-12a

Schuster DM, Nieh PT, Jani AB, et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pentetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 2014;191:1446-53.

Schuster DM, Nanni C, Fanti S, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014;55:1986-92

Schreibmann E, Schuster DM, Rossi PJ, et al. Image-guided planning for prostate carcinomas with incorporation of anti-3-[18F]FACBC (fluciclovine) positron emission tomography: workflow and initial findings from a randomized trial. Int J Rad Oncol Biol Phys 2016;96:206-13

### **Indication**

Axumin™ (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

### **Important Safety Information**

Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.

Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.

Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.

Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Full Axumin prescribing information is available at: [www.axumin.com](http://www.axumin.com).